Instil Bio, Inc. TIL

TIL Company Overview

Instil Bio, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer and autoimmune diseases. The company operates within the biotechnology and immunotherapy industries, with an emphasis on engineered T-cell therapies and related biologic platforms. Historically, Instil Bio concentrated on tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, but the company later expanded its strategic focus toward next-generation cell therapies and autoimmune applications through licensing and platform collaborations. Its primary value drivers are research and development capabilities, intellectual property related to cell engineering technologies, and partnerships supporting clinical advancement.

The company was founded in 2018 and is headquartered in Dallas, Texas. Instil Bio became publicly traded on Nasdaq under the ticker TIL in 2021. Over time, the company restructured portions of its oncology pipeline and redirected capital toward platform technologies viewed as having broader therapeutic potential. Public filings and investor materials indicate that Instil Bio’s strategy has evolved from a narrowly focused oncology developer into a broader cell therapy platform company pursuing differentiated immune-cell engineering approaches.